Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
ROS are a risk factor of several cardiovascular disorders and interfere with NO/soluble guanylyl cyclase/ cyclic GMP (NO/sGC/cGMP) signaling through scavenging of NO and formation of the strong oxidant peroxynitrite.Increased oxidative stress affects the heme-containing NO receptor sGC by both decreasing its expression levels and impairing NO-induced activation, making vasodilator therapy with NO donors less effective.Here we show in vivo that oxidative stress and related vascular disease states, including human diabetes mellitus, led to an sGC that was indistinguishable from the in vitro oxidized/heme-free enzyme.This sGC variant represents what we believe to be a novel cGMP signaling entity that is unresponsive to NO and prone to degradation.Whereas high-affinity ligands for the unoccupied heme pocket of sGC such as zinc-protoporphyrin IX and the novel NO-independent sGC activator 4-[((4-carboxybutyl){2-[(4-pheneth ylbenzyl)oxy]phenethyl}amino) methyl [benzoic]acid (BAY 58-2667) stabilized the enzyme, only the latter activated the NO-insensitive sGC variant.Importantly, in isolated cells, in blood vessels, and in vivo, BAY 58-2667 was more effective and potentiated under pathophysiological and oxidative stress conditions.This therapeutic principle preferentially dilates diseased versus normal blood vessels and may have far-reaching implications for the currently investigated clinical use of BAY 58-2667 as a unique diagnostic tool and highly innovative vascular therapy.Nonstandard abbreviations used: BAY 41-2272, 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine; BAY 58-2667, 4-[((4-carboxybutyl){2-[(4-phenethylbenzyl)oxy] phenethyl}amino) methyl [benzoic]acid; BNP, B-type natriuretic peptide; cGMP, cyclic GMP; DEA/NO, 2-(N,N-diethylamino)-diazenolate-2-oxide; EC50, 50% effective concentration; GTN, glycerol trinitrate; l-NAME, N-nitro-l-arginine methylester; NAC, N-acetyl-cysteine; NZW, New Zealand (rabbits); ODQ, 1H-[1,2,4]oxadiazolo [3,4-a]quinoxalin-1-one; ONOO -, peroxynitrite; PDE, phosphodiesterase; PE, phenylephrine; PPIX, protoporphyrin IX; SIN-1, 3-morpholino-sydnonimine hydrochloride; sGC, soluble guanylyl cyclase; SHR, spontaneously hypertensive rats; TG(mRen2)27 rats, hypertensive transgenic renin rats; U46619, 9,11-dideoxy-9a,11a-methanoepoxyprostaglandin F2a; WHHL, Watanabe heritable hyperlipidemic (rabbits). Conflict of interest:Johannes-Peter Stasch and Andreas Knorr are currently full-time employees of Bayer HealthCare.Peter M. Schmidt was employed from 2000 to 2003 by Bayer HealthCare.Harald Lapp is the principal investigator of a clinical study of patients with acute decompensated heart failure using BAY 58-2667.Adrian Tersteegen is currently employed by Bayer HealthCare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide
Pryor, W. A., & Squadrito, G. L. (1995) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1995.268.5.l699 · Cited by 1,511 · cited 3×
“To address the effect of the Fe2+/Fe3+ sGC redox ratio on the BAY 58-2667 response, heme-containing and heme-free sGC were incubated with increasing concentrations of 1H-[1,2,4]oxadiazolo [3,4-a]quinoxalin-1-one (ODQ) in the presence of BAY 58-2667.”
BackgroundMethodWarnholtz, A., Nickenig, G., Schulz, E., Macharzina, R., Bräsen, J. H., Skatchkov, M., Heitzer, T., Stasch, J. P., Griendling, K. K., Harrison, D. G., et al. (1999) · Circulation · doi:10.1161/01.cir.99.15.2027 · Cited by 676
Self-citationInhibition of nitric oxide synthesis by methylene blue
Mayer, B., Brunner, F., & Schmidt, K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90072-5 · Cited by 535
Darley-usmar, V. M., Hogg, N., O'leary, V. J., Wilson, M. T., & Moncada, S. (1992) · Free Radical Research Communications · doi:10.3109/10715769209061085 · Cited by 456
Schrammel, A., Behrends, S., Schmidt, K., Koesling, D., & Mayer, B. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09113-8 · Cited by 360
Stasch, J., Schmidt, P., Alonso‐Alija, C., Apeler, H., Dembowsky, K., Haerter, M., Heil, M., Minuth, T., Perzborn, E., Pleiss, U., et al. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704778 · Cited by 313
Self-citationEndothelial Function and Oxidant Stress
Harrison, D. G. (1997) · Clinical Cardiology · doi:10.1002/j.1932-8737.1997.tb00007.x · Cited by 304
Ignarro, L. J., Degnan, J. N., Baricos, W. H., Kadowitz, P. J., & Wolin, M. S. (1982) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(82)90008-3 · Cited by 265
Downregulation of Soluble Guanylyl Cyclase in Young and Aging Spontaneously Hypertensive Rats
Ruetten, H., Zabel, U., Linz, W., & Schmidt, H. H. H. W. (1999) · Circulation Research · doi:10.1161/01.res.85.6.534 · Cited by 209
Self-citationSpare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system
Mergia, E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27657 · Cited by 196
Cited by
Superoxide Dismutases: Role in Redox Signaling, Vascular Function, and Diseases
Fukai, T., & Ushio-Fukai, M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3999 · Cited by 1,983
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
“Finally, oxidative stress can render the receptor for NO dysfunctional, as the NO-binding haem group of soluble guanylyl cyclase, which normally exists in the Fe 2+ state, is highly susceptible to oxidation to the Fe 3+ state, which is associated with a markedly reduced affinity of the enzyme for N”
BackgroundConcepts of neural nitric oxide‐mediated transmission
Garthwaite, J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06285.x · Cited by 807
Nitric oxide signalling in cardiovascular health and disease
Farah, C., Michel, L. Y. M., & Balligand, J.-L. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.224 · Cited by 779
Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., Schmidt, H. H. H. W., & Stasch, J.-P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2038 · Cited by 749
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Self-citationSources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Targeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
“According to more recent data, evaluation of endothelial function in itself may not be sufficient as vascular function is also affected by processes within the smooth muscle (e.g. activity of soluble guanylyl cyclase [sGC]) (Stasch et al., 2006).”
BackgroundKynurenine is an endothelium-derived relaxing factor produced during inflammation
Wang, Y., Liu, H., McKenzie, G., Witting, P. K., Stasch, J.-P., Hahn, M., Changsirivathanathamrong, D., Wu, B. J., Ball, H. J., Thomas, S. R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2092 · Cited by 446
Self-citationCyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Tsai, E. J., & Kass, D. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.009 · Cited by 420
Thomas, S. R., Witting, P. K., & Drummond, G. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2027 · Cited by 383
“Stasch and colleagues (453) reported that endothelial dysfunction during vascular disease states involves the accumulation of oxidized and/or hemefree sGC in diseased blood vessels, refractory from activation by NO (453).”
InfluentialNitroxyl (HNO): the Cinderella of the nitric oxide story
Irvine, J. C., Ritchie, R. H., Favaloro, J. L., Andrews, K. L., Widdop, R. E., & Kemp-Harper, B. K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.08.005 · Cited by 277
Self-citationMikhed, Y., Daiber, A., & Steven, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160715918 · Cited by 257
“Since the •NO target enzyme soluble guanylyl cyclase (sGC) is also subject to oxidative inactivation (S-oxidation, S-nitrosation, heme-oxidation) [102–108], it might be speculated that the aging process will lead to an inactivation or at least desensitization of the enzyme.”
BackgroundThe Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators
Follmann, M., Griebenow, N., Hahn, M. G., Hartung, I., Mais, F., Mittendorf, J., Schäfer, M., Schirok, H., Stasch, J., Stoll, F., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302588 · Cited by 200
Self-citationProtecting against vascular disease in brain
Faraci, F. M. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01310.2010 · Cited by 196
Wind, S., Beuerlein, K., Armitage, M. E., Taye, A., Kumar, A. H. S., Janowitz, D., Neff, C., Shah, A. M., Wingler, K., & Schmidt, H. H. H. W. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149187 · Cited by 181
Self-citationRole of nitrosative stress in the pathogenesis of diabetic vascular dysfunction
Szabo, C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00086.x · Cited by 165
“, 2007), and oxidative inactivation of guanylyl cyclase, the intracellular receptor of NO within the cytosol of the vascular smooth muscle cells (Stasch et al., 2006).”
BackgroundLapp, H., Mitrovic, V., Franz, N., Heuer, H., Buerke, M., Wolfertz, J., Mueck, W., Unger, S., Wensing, G., & Frey, R. (2009) · Circulation · doi:10.1161/circulationaha.108.800292 · Cited by 148
Self-citationReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications
Casas, A. I., Dao, V. T.-V., Daiber, A., Maghzal, G. J., Di Lisa, F., Kaludercic, N., Leach, S., Cuadrado, A., Jaquet, V., Seredenina, T., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6433 · Cited by 136
Self-citationReactive oxygen species and the control of vascular function
Wolin, M. S. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01167.2008 · Cited by 133
Nox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113
“Heme-free apo-sGC is essentially unresponsive to NO, but can bind sGC activators that occupy the empty sGC heme binding site and re-activate apo-sGC to the same Vmax as Fe(II)sGC in the presence of NO (Evgenov et al., 2006; Stasch et al., 2006).”
Self-citationGarthwaite, J. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0318-8 · Cited by 102
Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling
Rahaman, M. M., Nguyen, A. T., Miller, M. P., Hahn, S. A., Sparacino-Watkins, C., Jobbagy, S., Carew, N. T., Cantu-Medellin, N., Wood, K. C., Baty, C. J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310705 · Cited by 92
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88
Self-citationGladwin, M. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29807 · Cited by 85
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84
Thoonen, R., Cauwels, A., Decaluwe, K., Geschka, S., Tainsh, R. E., Delanghe, J., Hochepied, T., De Cauwer, L., Rogge, E., Voet, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9482 · Cited by 77
Self-citationProbing the presence of the ligand‐binding haem in cellular nitric oxide receptors
Roy, B., Mo, E., Vernon, J., & Garthwaite, J. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707687 · Cited by 62
Sharina, I. G., & Martin, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6687 · Cited by 19
Ghosh, A., & Stuehr, D. J. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6690 · Cited by 19
“This has increased interest toward developing drug candidatesthatcan activatesGCindependentofNOoritsheme (37, 76, 78) and has piqued interest in the cellular mechanisms that may control the heme content, protein associations, and activity of sGC.”
Redox regulation of responses to hypoxia and NO–cGMP signaling in pulmonary vascular pathophysiology
Wolin, M. S., Gupte, S. A., Mingone, C. J., Neo, B. H., Gao, Q., & Ahmad, M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05557.x · Cited by 17
Metadata
- Authors
- Stasch, J.-P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y., H.S., A. K., Meurer, S., Deile, M., Taye, A., Knorr, A., Lapp, H., Müller, H., Turgay, Y., Rothkegel, C., Tersteegen, A., Kemp-Harper, B., Müller-Esterl, W., & Schmidt, H. H. H. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-09-01
- Volume
- 116
- Issue
- 9
- Pages
- 2552-2561
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2113297587
- Cited by
- 455
- References
- 31
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.